INmune Bio (NASDAQ:INMB) Issues Earnings Results

INmune Bio (NASDAQ:INMB) released its quarterly earnings results on Thursday. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.11), Zacks reports. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 121.57%. During the same period last year, the company posted ($0.48) earnings per share.

INmune Bio Stock Performance

NASDAQ INMB traded up $0.19 during trading hours on Friday, hitting $6.04. 225,027 shares of the company traded hands, compared to its average volume of 228,751. The business’s 50-day moving average is $5.64 and its 200-day moving average is $7.78. The stock has a market capitalization of $119.35 million, a price-to-earnings ratio of -2.77 and a beta of 1.84. INmune Bio has a twelve month low of $4.78 and a twelve month high of $14.74.

Insider Activity at INmune Bio

In other news, CFO David J. Moss bought 7,690 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the purchase, the chief financial officer now owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other INmune Bio news, CFO David J. Moss acquired 7,690 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the purchase, the chief financial officer now directly owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David J. Moss acquired 10,000 shares of INmune Bio stock in a transaction on Monday, September 30th. The shares were bought at an average cost of $5.29 per share, with a total value of $52,900.00. Following the completion of the transaction, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at approximately $6,802,247.01. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 33,070 shares of company stock valued at $200,087. 35.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on INMB. Scotiabank started coverage on INmune Bio in a report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price objective for the company. Alliance Global Partners assumed coverage on shares of INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 price target for the company. Finally, Raymond James initiated coverage on shares of INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective on the stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.